A Phase 3 interventional study of Gepotidacin and Placebo matching nitrofurantoin in Urinary Tract Infections, sponsored by GlaxoSmithKline. Completed at 104 sites in 12 countries. Open to female participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2023-06-22.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Urinary Tract Infections by GlaxoSmithKline — 4 open to participants now, 4 under way, none of them phase 3. Urinary Tract Infections · GlaxoSmithKline.
Among the 14 studies in Urinary Tract Infections by GlaxoSmithKline, this one is the 2nd largest by enrollment of the 13 interventional ones that give a count, is the only one that started in 2019, is one of 4 in phase 3, and was the 4th registered.
804 studies on the registry are indexed under Urinary Tract Infections; 133 are open to participants now.
Browse Urinary Tract Infections studies →4 of the 14 studies in Urinary Tract Infections by GlaxoSmithKline are open now, in 2 countries. Recruiting first, the newest first:
GlaxoSmithKline · Sites in United States
Ages 18–50 · Women only · Healthy volunteers
GlaxoSmithKline · Sites in United States, South Africa
Ages 18–64 · Healthy volunteers
GlaxoSmithKline
Ages 15–50 · Women only
GlaxoSmithKline · Sites in United States
Ages 2–11
By country, each count listing its studies:
Of the 84 Urinary Tract Infections studies recruiting now, 50 (60%) set no upper age limit and 23 (27%) stop at 75 or younger; 15 take children under 18; 17 take healthy volunteers.
This study: 12 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 3 · Phase 3 4 · Phase 4 1
First in 2011; this study’s year is marked. 1 started in 2019.
This study's enrollment of 1,531 is above the median of 132 across 561 interventional studies indexed under Urinary Tract Infections.
Median enrollment 61 across the 13 interventional studies, 614 across the 1 observational. Of the 10 that completed or were terminated, 9 (90%) have results posted.
This tab as a report to print or save as PDF → With an account.
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
3 of the studies in Urinary Tract Infections by GlaxoSmithKline that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07645235GlaxoSmithKlineA Study to Evaluate Gepotidacin Exposure in Breast Milk of Healthy Lactating Women | 2027-05-17 |
| NCT06702449GlaxoSmithKlineA Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age | 2027-05-31 |
| NCT07371429GlaxoSmithKlineA Study in Pediatric Participants Aged ≥2 to <12 Years With a Suspected or Confirmed Bacterial Infection or Receiving Prophylaxis Antibiotics | 2027-08-23 |
Add all 3 to your calendar (.ics) → With an account.
Among the 14 studies in Urinary Tract Infections by GlaxoSmithKline, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study will be conducted to evaluate the therapeutic response (combined per participant microbiological and clinical response) of oral gepotidacin compared to oral nitrofurantoin for treatment of uncomplicated UTI (acute cystitis) in adolescent and adult female participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participant has any of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be administered oral doses of 1500 milligrams (mg) gepotidacin plus nitrofurantoin matching placebo twice daily (BID); approximately every 12 hours for 5 days
Drug: Gepotidacin · Drug: Placebo matching nitrofurantoin
Participants will be administered oral doses of 100 mg nitrofurantoin plus gepotidacin matching placebo BID; approximately every 12 hours for 5 days.
Drug: Nitrofurantoin · Drug: Placebo matching gepotidacin
Gepotidacin will be available as tablets containing 750 mg gepotidacin. Each dose should be taken with water after consumption of food.
Placebo matching nitrofurantoin will be available as over-encapsulated unit-dose capsules. Each dose should be taken with water after consumption of food.
Nitrofurantoin will be available as over-encapsulated capsules containing 25 mg nitrofurantoin macrocrystals and 75 mg nitrofurantoin. Each dose should be taken with water after consumption of food.
Placebo matching gepotidacin will be available as unit-dose gepotidacin placebo-to-match tablet. Each dose should be taken with water after consumption of food.
Number of Participants With Therapeutic Response (TR) (Combined Per Participant Clinical and Microbiological Response) at the Test-of-Cure (TOC) Visit - Micro-ITT NTF-S (IA Set)
Therapeutic response (success/failure) is a measure of the overall efficacy response. A therapeutic success referred to participants who had been deemed both a "microbiological success"(reduction of all qualifying bacterial uropathogens \[greater than or equal to {\>=}10\^5 colony-forming units per milliliter {CFU/mL}\] recovered at Baseline to less than (\<)10\^3 CFU/mL as observed on quantitative urine culture without the participant receiving other systemic antimicrobials before the TOC Visit) and a "clinical success" (resolution of signs and symptoms of acute cystitis present at Baseline \[and no new signs and symptoms\] without the participant receiving other systemic antimicrobials before the TOC Visit). Lack of clinical or microbiological success (including missing outcome assessments) was considered as therapeutic failure.
Time frame: TOC visit (Days 9 to 16)
Number of Participants With Therapeutic Response (TR) (Combined Per Participant Clinical and Microbiological Response) at the Test-of-Cure (TOC) Visit - Micro-ITT NTF-S Population
TR at TOC (success/failure) is a measure of the overall efficacy response. A therapeutic success at TOC referred to participant who have been deemed both a microbiological success (reduction of all qualifying bacterial uropathogens recovered at Baseline \[BL\] to \<10\^3 colony forming units per milliliter \[CFU/mL\] without receiving other systemic antimicrobials \[AB\] before the TOC visit) and a clinical success (resolution of symptoms of acute cystitis present at BL and no new symptoms without receiving other AB before the TOC visit \[or AB for uUTI on day of TOC visit\]). Lack of clinical or microbiological success (including missing outcome assessments) was considered as therapeutic failure.
Time frame: TOC visit (Days 9 to 16)
Number of Participants With Clinical Outcome at the TOC Visit - Micro-ITT NTF-S Population
Clinical outcomes at TOC were categorized as clinical resolution, clinical improvement, clinical worsening and unable to determine. Clinical resolution at TOC was defined as resolution of signs and symptoms of acute cystitis present at baseline (BL) (and no symptoms) without receiving any other AB before the TOC visit. Clinical improvement at TOC was defined as improvement (but not complete resolution) in total symptom score (CSS) from BL, without receiving any other AB before the TOC visit. Clinical worsening at TOC was defined as worsening or no change in CSS from BL or received other AB for the current infection (uUTI) before or on the date of the TOC visit. Unable to determine outcome criteria were: BL score is missing (and thus improvement/worsening cannot be determined), TOC assessment is missing, or receipt of other AB not for the current infection before the TOC visit (unless clinical worsening outcome criteria were met).
Time frame: TOC visit (Days 9 to 16)
Number of Participants With Clinical Response at the TOC Visit - Micro-ITT NTF-S Population
Clinical response at TOC was categorized as clinical success and clinical failure. Clinical success at TOC was defined as resolution of symptoms of acute cystitis present at BL (and no new symptoms), without receiving any other AB before the TOC visit. Lack of resolution, including receipt of an AB for uUTI at the TOC visit, or a missing outcome assessment was defined as Clinical Failure at TOC.
Time frame: TOC visit (Days 9 to 16)
Number of Participants With Microbiological Outcome (MO) at the TOC Visit - Micro-ITT NTF-S Population
Participant-level MOs at TOC were categorized as microbiological eradication (ME), microbiological persistence (MP), microbiological recurrence (MR) and unable to determine (UTD). ME at TOC was defined as all baseline qualifying uropathogens (QUP) have an outcome of eradication at TOC (i.e., \<10\^3 CFU/mL without the participant receiving other systemic antimicrobials before the TOC Visit). MP at TOC was defined as at least 1 QUP has an outcome of persistence (≥10\^3 CFU/mL) at TOC. MR at TOC was defined as at least 1 QUP had an outcome of recurrence and none have an outcome of persistence at TOC. UTD at TOC was defined as all QUP outcomes are UTD at TOC.
Time frame: TOC Visit (Days 9 to 16)
Number of Participants With Microbiological Response at the TOC Visit - Micro-ITT NTF-S Population
Participant-level microbiological response at TOC was categorized as microbiological success and microbiological failure. Microbiological success at TOC was defined as all baseline qualifying uropathogens (QUP)s had a microbiological outcome of eradication at TOC visit. Microbiological failure was defined as lack of microbiological success, including those participants with UTD outcomes.
Time frame: TOC visit (Days 9 to 16)
Number of Participants With Therapeutic Response (TR) (Combined Per Participant Clinical and Microbiological Response) at the Follow up (FU) Visit-Micro-ITT NTF-S Population
TR at FU was categorized as therapeutic success and therapeutic failure. A therapeutic success at FU referred to participants who have been deemed both a microbiological success (reduction of all QUPs recovered at BL to \<10\^3 CFU/mL, following microbiological eradication at the TOC visit, without receiving other AB before the FU visit) and a clinical success (resolution of signs and symptoms of acute cystitis demonstrated at the TOC visit persist at the FU visit and no new signs and symptoms, without receiving other AB before the FU visit \[or AB for uUTI on day of FU visit\]). Lack of clinical or microbiological success (including missing outcome assessments) was considered as therapeutic failure.
Time frame: FU visit (Days 21 to 31)
Number of Participants With Clinical Outcome at the Follow up (FU) Visit - Micro-ITT NTF-S Population
Clinical outcomes at FU were categorized as SCR, DCR, CI, CW, CR and UTD. SCR at FU was resolution of symptoms of acute cystitis demonstrated at the TOC persist at the FU (and no symptoms), without receiving other AB before the FU. DCR at FU was resolution of symptoms of acute cystitis present at BL after clinical failure at TOC without receiving AB before FU. CI at FU was improvement in CSS from BL, but not complete resolution without receiving AB before FU. CW at FU was worsening or no change in CSS at FU compared to BL after clinical failure at TOC or receiving other AB for the current infection (uUTI) before or on the date of the FU. CR at FU was symptoms of acute cystitis reoccur at FU after clinical success at TOC. Unable to determine outcome criteria at FU were BL score missing, FU assessment missing or received other AB not for the current infection (uUTI) prior to the assessment (unless CS or CR outcome criteria were met).
Time frame: FU visit (Days 21 to 31)
Number of Participants With Clinical Response at the Follow up (FU) Visit - Micro-ITT NTF-S Population
Clinical response at FU was categorized as clinical success and clinical failure. Clinical success at FU was defined as resolution of symptoms of acute cystitis demonstrated at TOC persist at the FU visit (and no new symptoms), without receiving other AB before the FU visit. Lack of sustained clinical resolution or a missing outcome assessment was defined as clinical failure.
Time frame: FU visit (Days 21 to 31)
Number of Participants With Microbiological Outcome (MO) at the Follow up (FU) Visit - Micro-ITT NTF-S Population
Participant-level MOs at FU were categorized as sustained microbiological eradication (SME), microbiological recurrence (MR), microbiological persistence (MP), delayed microbiological eradication (DME) and unable to determine (UTD). SME at FU was defined as all baseline QUPs had an outcome of sustained eradication at FU (i.e., \<10\^3 CFU/mL without the participant receiving other systemic antimicrobials before the FU Visit). MR at FU was defined as at least one QUP had an outcome of recurrence (≥10\^3 CFU/mL) and none had an outcome of persistence at FU. MP at FU was defined as at least one QUP had an outcome of persistence at FU. DME at FU was defined as at least one QUP had an outcome of delayed eradication and none had an outcome of persistence or recurrence at FU. UTD at FU was defined as all QUP outcomes were unable to determine at FU.
Time frame: FU visit (Days 21 to 31)
Number of Participants With Microbiological Response at the Follow up (FU) Visit - Micro-ITT NTF-S Population
Participant- level microbiological response at FU was categorized as microbiological success and microbiological failure. Microbiological success at FU was defined as all baseline QUPs had a microbiological outcome of sustained eradication at FU visit. Microbiological failure at FU was defined as not meeting criteria of microbiological success including those participants with UTD outcome.
Time frame: FU visit (Days 21 to 31)
Number of Participants With Clinical Outcome at the TOC Visit - Intent-to-Treat (ITT) Population
Clinical outcomes at TOC were categorized as clinical resolution, clinical improvement, clinical worsening and unable to determine. Clinical resolution at TOC was defined as resolution symptoms of acute cystitis present at baseline (BL) (and no symptoms) without receiving any other AB before the TOC visit. Clinical improvement at TOC was defined as improvement (but not complete resolution) in CSS from BL, without receiving any other AB before the TOC visit. Clinical worsening at TOC was defined as worsening or no change in CSS from BL or received other AB for the current infection (uUTI) before or on the date of the TOC visit. Unable to determine outcome criteria were: BL score is missing (and thus improvement/worsening cannot be determined), TOC assessment is missing, or receipt of other AB not for the current infection before the TOC visit (unless clinical worsening outcome criteria were met).
Time frame: TOC visit (Days 9 to 16)
Number of Participants With Clinical Response at the TOC Visit - Intent-to-Treat (ITT) Population
Clinical response at TOC was categorized as clinical success and clinical failure. Clinical success at TOC was defined as resolution of signs and symptoms of acute cystitis present at BL (and no new symptoms), without receiving any other AB before the TOC visit. Lack of resolution, including receipt of an AB for uUTI at the TOC visit, or a missing outcome assessment was defined as Clinical Failure.
Time frame: TOC visit (Days 9 to 16)
Number of Participants With Clinical Outcome at the Follow up (FU) Visit - Intent-to-Treat (ITT) Population
Clinical outcomes at FU were categorized as Sustained Clinical Response (SCR), Delayed Clinical Response (DCR), CI, CW, Clinical Recurrence (CR) and UTD. SCR at FU was resolution of symptoms of acute cystitis demonstrated at TOC persist at the FU (and no symptoms), without receiving other AB before the FU. DCR at FU was resolution of symptoms of acute cystitis present at BL after clinical failure at TOC without receiving AB before FU. CI at FU was improvement in CSS from BL, but not complete resolution without receiving AB before FU. CW at FU was worsening or no change in CSS at FU compared to BL after clinical failure at TOC or receiving other AB for the current infection (uUTI) before or on the date of the FU. CR at FU was symptoms of acute cystitis reoccur at FU after clinical success at TOC. UTD outcome criteria at FU were BL score missing, FU assessment missing or received other AB not for current infection (uUTI) prior to assessment (unless CS or CR outcome criteria were met).
Time frame: FU visit (Days 21 to 31)
Number of Participants With Clinical Response at the Follow up (FU) Visit - Intent-to-Treat (ITT) Population
Clinical response at FU was categorized as clinical success and clinical failure. Clinical success at FU was defined as resolution of symptoms of acute cystitis demonstrated at TOC persist at the FU visit (and no new symptoms), without receiving other AB before the FU visit. Lack of sustained clinical resolution or a missing outcome assessment was defined as clinical failure.
Time frame: FU visit (Days 21 to 31)
Plasma Concentration of Gepotidacin
Blood samples were collected for plasma concentration of gepotidacin.
Time frame: Baseline (Day 1) 0-2 hour (h) and >2h post-dose; On-therapy (Day 2), morning (am) pre-dose, 0-6h, 6-8h, 8-10h, 10-12h post-dose, 0-2h, >2h evening (pm) post-dose; On-therapy (Day 3 to 5), 0-6h, 6-8h, 8-10h, 10-12h post-dose
Urine Concentration of Gepotidacin
Urine samples were collected from participants.
Time frame: Baseline (Day 1) 0-2 hour (h) and >2h post-dose; On-therapy (Day 2), morning (am) pre-dose, 0-6h, 6-8h, 8-10h, 10-12h post-dose, 0-2h, >2h evening (pm) post-dose; On-therapy (Day 3 to 5), 0-6h, 6-8h, 8-10h, 10-12h post-dose
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment.
Time frame: From the time of first dose (Day 1) through the final follow-up visit (Day 21-31)
Number of Participants With Serious Adverse Events (SAEs)
An SAE is defined as any untoward medical occurrence that, at any dose may result in death or is life-threatening or requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity or is a congenital anomaly/birth defect or any other situation according to medical or scientific judgment or is associated with liver injury and impaired liver function.
Time frame: From the time of first dose (Day 1) through the final follow-up visit (Day 21-31)
Change From Baseline in Hematology Parameters - Neutrophil Count, Lymphocyte Count, Monocyte Count, Eosinophil Count, Basophil Count and Platelet Count at On Therapy and Test of Cure Visit
Blood samples were collected for the analysis of hematology parameters: neutrophil count, lymphocyte count, monocyte count, eosinophil count, basophil count and platelet count. Baseline is defined as the latest pre-dose assessment with a non-missing value.
Time frame: Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)
Change From Baseline in Hematology Parameter-hemoglobin Level at On Therapy and Test of Cure Visit
Blood samples were collected for the analysis of hemoglobin level. Baseline is defined as the latest pre-dose assessment with a non-missing value.
Time frame: Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)
Change From Baseline in Hematology Parameter- Hematocrit Level at On Therapy and Test of Cure Visit
Blood samples were collected for the analysis of hematocrit level. Baseline is defined as the latest pre-dose assessment with a non-missing value.
Time frame: Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)
Change From Baseline in Hematology Parameter- Erythrocytes Count at On Therapy and Test of Cure Visit
Blood samples were collected for the analysis of erythrocytes count. Baseline is defined as the latest pre-dose assessment with a non-missing value.
Time frame: Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)
Change From Baseline in Hematology Parameter - Mean Corpuscular Hemoglobin (MCH) at On Therapy and Test of Cure Visit
Blood samples were collected for the analysis of MCH. Baseline is defined as the latest pre-dose assessment with a non-missing value.
Time frame: Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)
Change From Baseline in Hematology Parameter - Mean Corpuscular Volume (MCV) at On Therapy and Test of Cure Visit
Blood samples were collected for the analysis of MCV. Baseline is defined as the latest pre-dose assessment with a non-missing value.
Time frame: Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)
Change From Baseline in Clinical Chemistry Parameters - Serum Urea Nitrogen, Glucose, Calcium, Chloride, Sodium, Magnesium, Phosphate, and Potassium Levels at On Therapy and Test of Cure Visit
Blood samples were collected for the analysis of clinical chemistry parameters. Baseline is defined as the latest pre-dose assessment with a non-missing value
Time frame: Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)
Change From Baseline in Clinical Chemistry Parameters - Total Bilirubin, Direct Bilirubin and Creatinine Levels at On Therapy and Test of Cure Visit
Blood samples were collected for the analysis of clinical chemistry parameters. Baseline is defined as the latest pre-dose assessment with a non-missing value.
Time frame: Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)
Change From Baseline in Clinical Chemistry Parameters - Albumin and Protein Levels at On Therapy and Test of Cure Visit
Blood samples were collected for the analysis of clinical chemistry parameters. Baseline is defined as the latest pre-dose assessment with a non-missing value.
Time frame: Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)
Change From Baseline in Clinical Chemistry Parameters - Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) and Alkaline Phosphatase (ALP) Levels at On Therapy and Test of Cure Visit
Blood samples were collected for the analysis of clinical chemistry parameters. Baseline is defined as the latest pre-dose assessment with a non-missing value.
Time frame: Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)
Number of Participants With Urinalysis Dipstick Results at Baseline, On Therapy and Test of Cure Visit
Urine samples were collected for urinalysis: Urine Glucose (GLU), Urine Protein (PRO), Urine Occult Blood (BLO), Urine Ketones (KET), Urine Nitrite (NIT) and Urine Leukocyte Esterase (LEU). Baseline is defined as the latest pre-dose assessment with a non-missing value. The dipstick test gives results in a semi-quantitative manner, and results can be read as Negative, Trace, Small, Moderate, Large, Positive, 50 mg/dL, 150 mg/dL, \>=500 mg/dL, 30 mg/dL, 100 mg/dL, 200 mg/dL, 5 mg/dL, 20 mg/dL and 80 mg/dL indicating concentrations in the urine sample. In the row title (GLU, Baseline, Negative), GLU indicates parameter, Baseline is the visit and Negative indicates the concentration in the urine sample. Data is presented in similar manner for all other parameters.
Time frame: Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)
Absolute Mean Values of Urine Specific Gravity at Baseline, On Therapy and Test of Cure Visit
Urine samples were collected from participants to assess urine specific gravity. Baseline is defined as the latest pre-dose assessment with a non-missing value.
Time frame: Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)
Absolute Mean Values of Urine Potential of Hydrogen (pH) at Baseline, On Therapy and Test of Cure Visit
Urine samples were collected from participants to assess urine pH levels. Baseline is defined as the latest pre-dose assessment with a non-missing value.
Time frame: Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at On-Therapy and Test of Cure Visit
SBP and DBP were measured in a semi-supine position after 5 minutes rest. Baseline is defined as the latest pre-dose assessment with a non-missing value.
Time frame: Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)
Change From Baseline in Pulse Rate at On Therapy and Test of Cure Visit
Pulse rate was measured in a semi-supine position after 5 minutes rest. Baseline is defined as the latest pre-dose assessment with a non-missing value.
Time frame: Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)
Change From Baseline in Body Temperature at On Therapy and Test of Cure Visit
Temperature was measured in a semi-supine position after 5 minutes rest. Baseline is defined as the latest pre-dose assessment with a non-missing value.
Time frame: Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)
| Milestone | Gepotidacin | Nitrofurantoin |
|---|---|---|
| Started | 767 | 764 |
| Safety population | 766 | 760 |
| Microbiological itt (micro itt) population | 401 | 365 |
| Micro-itt ntf-s population | 336 | 298 |
| Micro-itt ntf-s (ia set) population | 320 | 287 |
| Completed | 734 | 736 |
| Not completed | 33 | 28 |
| Withdrew: Adverse event | 8 | 6 |
| Withdrew: Lost to follow-up | 8 | 2 |
| Withdrew: Withdrawal by subject | 16 | 16 |
| Withdrew: Participant not able to swallow the tablet | 1 | 0 |
| Withdrew: Physician decision | 0 | 2 |
| Withdrew: Protocol deviation | 0 | 2 |
Therapeutic response (success/failure) is a measure of the overall efficacy response. A therapeutic success referred to participants who had been deemed both a "microbiological success"(reduction of all qualifying bacterial uropathogens \[greater than or equal to {\>=}10\^5 colony-forming units per milliliter {CFU/mL}\] recovered at Baseline to less than (\<)10\^3 CFU/mL as observed on quantitative urine culture without the participant receiving other systemic antimicrobials before the TOC Visit) and a "clinical success" (resolution of signs and symptoms of acute cystitis present at Baseline \[and no new signs and symptoms\] without the participant receiving other systemic antimicrobials before the TOC Visit). Lack of clinical or microbiological success (including missing outcome assessments) was considered as therapeutic failure.
| Participants | Gepotidacin | Nitrofurantoin |
|---|---|---|
| Therapeutic Success | 162 | 135 |
| Therapeutic Failure | 158 | 152 |
TR at TOC (success/failure) is a measure of the overall efficacy response. A therapeutic success at TOC referred to participant who have been deemed both a microbiological success (reduction of all qualifying bacterial uropathogens recovered at Baseline \[BL\] to \<10\^3 colony forming units per milliliter \[CFU/mL\] without receiving other systemic antimicrobials \[AB\] before the TOC visit) and a clinical success (resolution of symptoms of acute cystitis present at BL and no new symptoms without receiving other AB before the TOC visit \[or AB for uUTI on day of TOC visit\]). Lack of clinical or microbiological success (including missing outcome assessments) was considered as therapeutic failure.
| Participants | Gepotidacin | Nitrofurantoin |
|---|---|---|
| Therapeutic Success | 174 | 140 |
| Therapeutic Failure | 162 | 158 |
Clinical outcomes at TOC were categorized as clinical resolution, clinical improvement, clinical worsening and unable to determine. Clinical resolution at TOC was defined as resolution of signs and symptoms of acute cystitis present at baseline (BL) (and no symptoms) without receiving any other AB before the TOC visit. Clinical improvement at TOC was defined as improvement (but not complete resolution) in total symptom score (CSS) from BL, without receiving any other AB before the TOC visit. Clinical worsening at TOC was defined as worsening or no change in CSS from BL or received other AB for the current infection (uUTI) before or on the date of the TOC visit. Unable to determine outcome criteria were: BL score is missing (and thus improvement/worsening cannot be determined), TOC assessment is missing, or receipt of other AB not for the current infection before the TOC visit (unless clinical worsening outcome criteria were met).
| Participants | Gepotidacin | Nitrofurantoin |
|---|---|---|
| Clinical resolution | 224 | 196 |
| Clinical improvement (CI) | 82 | 75 |
| Clinical worsening (CW) | 9 | 16 |
| Unable to determine | 21 | 11 |
Clinical response at TOC was categorized as clinical success and clinical failure. Clinical success at TOC was defined as resolution of symptoms of acute cystitis present at BL (and no new symptoms), without receiving any other AB before the TOC visit. Lack of resolution, including receipt of an AB for uUTI at the TOC visit, or a missing outcome assessment was defined as Clinical Failure at TOC.
| Participants | Gepotidacin | Nitrofurantoin |
|---|---|---|
| Clinical success | 224 | 196 |
| Clinical failure | 112 | 102 |
Participant-level MOs at TOC were categorized as microbiological eradication (ME), microbiological persistence (MP), microbiological recurrence (MR) and unable to determine (UTD). ME at TOC was defined as all baseline qualifying uropathogens (QUP) have an outcome of eradication at TOC (i.e., \<10\^3 CFU/mL without the participant receiving other systemic antimicrobials before the TOC Visit). MP at TOC was defined as at least 1 QUP has an outcome of persistence (≥10\^3 CFU/mL) at TOC. MR at TOC was defined as at least 1 QUP had an outcome of recurrence and none have an outcome of persistence at TOC. UTD at TOC was defined as all QUP outcomes are UTD at TOC.
| Participants | Gepotidacin | Nitrofurantoin |
|---|---|---|
| Microbiological Eradication (ME) | 244 | 199 |
| Microbiological Persistence (MP) | 15 | 21 |
| Microbiological Recurrence (MR) | 36 | 52 |
| Unable to determine (UTD) | 41 | 26 |
Participant-level microbiological response at TOC was categorized as microbiological success and microbiological failure. Microbiological success at TOC was defined as all baseline qualifying uropathogens (QUP)s had a microbiological outcome of eradication at TOC visit. Microbiological failure was defined as lack of microbiological success, including those participants with UTD outcomes.
| Participants | Gepotidacin | Nitrofurantoin |
|---|---|---|
| Microbiological success | 244 | 199 |
| Microbiological failure | 92 | 99 |
TR at FU was categorized as therapeutic success and therapeutic failure. A therapeutic success at FU referred to participants who have been deemed both a microbiological success (reduction of all QUPs recovered at BL to \<10\^3 CFU/mL, following microbiological eradication at the TOC visit, without receiving other AB before the FU visit) and a clinical success (resolution of signs and symptoms of acute cystitis demonstrated at the TOC visit persist at the FU visit and no new signs and symptoms, without receiving other AB before the FU visit \[or AB for uUTI on day of FU visit\]). Lack of clinical or microbiological success (including missing outcome assessments) was considered as therapeutic failure.
| Participants | Gepotidacin | Nitrofurantoin |
|---|---|---|
| Therapeutic Success | 117 | 94 |
| Therapeutic Failure | 219 | 204 |
Clinical outcomes at FU were categorized as SCR, DCR, CI, CW, CR and UTD. SCR at FU was resolution of symptoms of acute cystitis demonstrated at the TOC persist at the FU (and no symptoms), without receiving other AB before the FU. DCR at FU was resolution of symptoms of acute cystitis present at BL after clinical failure at TOC without receiving AB before FU. CI at FU was improvement in CSS from BL, but not complete resolution without receiving AB before FU. CW at FU was worsening or no change in CSS at FU compared to BL after clinical failure at TOC or receiving other AB for the current infection (uUTI) before or on the date of the FU. CR at FU was symptoms of acute cystitis reoccur at FU after clinical success at TOC. Unable to determine outcome criteria at FU were BL score missing, FU assessment missing or received other AB not for the current infection (uUTI) prior to the assessment (unless CS or CR outcome criteria were met).
| Participants | Gepotidacin | Nitrofurantoin |
|---|---|---|
| Sustained clinical resolution (SCR) | 184 | 162 |
| Delayed clinical resolution (DCR) | 61 | 44 |
| Clinical improvement (CI) | 28 | 27 |
| Clinical worsening (CW) | 12 | 23 |
| Clinical recurrence (CR) | 11 | 11 |
| Unable to determine (UTD) | 40 | 31 |
Clinical response at FU was categorized as clinical success and clinical failure. Clinical success at FU was defined as resolution of symptoms of acute cystitis demonstrated at TOC persist at the FU visit (and no new symptoms), without receiving other AB before the FU visit. Lack of sustained clinical resolution or a missing outcome assessment was defined as clinical failure.
| Participants | Gepotidacin | Nitrofurantoin |
|---|---|---|
| Clinical success | 184 | 162 |
| Clinical failure | 152 | 136 |
Participant-level MOs at FU were categorized as sustained microbiological eradication (SME), microbiological recurrence (MR), microbiological persistence (MP), delayed microbiological eradication (DME) and unable to determine (UTD). SME at FU was defined as all baseline QUPs had an outcome of sustained eradication at FU (i.e., \<10\^3 CFU/mL without the participant receiving other systemic antimicrobials before the FU Visit). MR at FU was defined as at least one QUP had an outcome of recurrence (≥10\^3 CFU/mL) and none had an outcome of persistence at FU. MP at FU was defined as at least one QUP had an outcome of persistence at FU. DME at FU was defined as at least one QUP had an outcome of delayed eradication and none had an outcome of persistence or recurrence at FU. UTD at FU was defined as all QUP outcomes were unable to determine at FU.
| Participants | Gepotidacin | Nitrofurantoin |
|---|---|---|
| Sustained microbiological eradication (SME) | 174 | 136 |
| Microbiological persistence (MP) | 32 | 38 |
| Microbiological recurrence (MR) | 36 | 35 |
| Delayed microbiological eradication (DME) | 34 | 31 |
| Unable to determine (UTD) | 60 | 58 |
Participant- level microbiological response at FU was categorized as microbiological success and microbiological failure. Microbiological success at FU was defined as all baseline QUPs had a microbiological outcome of sustained eradication at FU visit. Microbiological failure at FU was defined as not meeting criteria of microbiological success including those participants with UTD outcome.
| Participants | Gepotidacin | Nitrofurantoin |
|---|---|---|
| Microbiological Success | 174 | 136 |
| Microbiological Failure | 162 | 162 |
Clinical outcomes at TOC were categorized as clinical resolution, clinical improvement, clinical worsening and unable to determine. Clinical resolution at TOC was defined as resolution symptoms of acute cystitis present at baseline (BL) (and no symptoms) without receiving any other AB before the TOC visit. Clinical improvement at TOC was defined as improvement (but not complete resolution) in CSS from BL, without receiving any other AB before the TOC visit. Clinical worsening at TOC was defined as worsening or no change in CSS from BL or received other AB for the current infection (uUTI) before or on the date of the TOC visit. Unable to determine outcome criteria were: BL score is missing (and thus improvement/worsening cannot be determined), TOC assessment is missing, or receipt of other AB not for the current infection before the TOC visit (unless clinical worsening outcome criteria were met).
| Participants | Gepotidacin | Nitrofurantoin |
|---|---|---|
| Clinical resolution | 497 | 484 |
| Clinical improvement | 194 | 206 |
| Clinical worsening | 26 | 37 |
| Unable to determine | 50 | 37 |
Clinical response at TOC was categorized as clinical success and clinical failure. Clinical success at TOC was defined as resolution of signs and symptoms of acute cystitis present at BL (and no new symptoms), without receiving any other AB before the TOC visit. Lack of resolution, including receipt of an AB for uUTI at the TOC visit, or a missing outcome assessment was defined as Clinical Failure.
| Participants | Gepotidacin | Nitrofurantoin |
|---|---|---|
| Clinical success | 497 | 484 |
| Clinical failure | 270 | 280 |
Clinical outcomes at FU were categorized as Sustained Clinical Response (SCR), Delayed Clinical Response (DCR), CI, CW, Clinical Recurrence (CR) and UTD. SCR at FU was resolution of symptoms of acute cystitis demonstrated at TOC persist at the FU (and no symptoms), without receiving other AB before the FU. DCR at FU was resolution of symptoms of acute cystitis present at BL after clinical failure at TOC without receiving AB before FU. CI at FU was improvement in CSS from BL, but not complete resolution without receiving AB before FU. CW at FU was worsening or no change in CSS at FU compared to BL after clinical failure at TOC or receiving other AB for the current infection (uUTI) before or on the date of the FU. CR at FU was symptoms of acute cystitis reoccur at FU after clinical success at TOC. UTD outcome criteria at FU were BL score missing, FU assessment missing or received other AB not for current infection (uUTI) prior to assessment (unless CS or CR outcome criteria were met).
| Participants | Gepotidacin | Nitrofurantoin |
|---|---|---|
| Sustained clinical resolution (SCR) | 421 | 404 |
| Delayed clinical resolution (DCR) | 130 | 127 |
| Clinical improvement (CI) | 75 | 71 |
| Clinical worsening (CW) | 29 | 48 |
| Clinical recurrence (CR) | 25 | 30 |
| Unable to determine (UTD) | 87 | 84 |
Clinical response at FU was categorized as clinical success and clinical failure. Clinical success at FU was defined as resolution of symptoms of acute cystitis demonstrated at TOC persist at the FU visit (and no new symptoms), without receiving other AB before the FU visit. Lack of sustained clinical resolution or a missing outcome assessment was defined as clinical failure.
| Participants | Gepotidacin | Nitrofurantoin |
|---|---|---|
| Clinical success | 421 | 404 |
| Clinical failure | 346 | 360 |
Blood samples were collected for plasma concentration of gepotidacin.
| Microgram/millilitre (ug/mL) | Gepotidacin |
|---|---|
| Baseline Day 1, 0-2hour (h) post-dose | 8.52 ± 84.21 |
| Baseline Day 1, >2h post-dose | 2.96 ± 1.865 |
| On-Therapy Day 2, am, pre-dose | 3.48 ± 21.58 |
| On-Therapy Day 2, 0-6h, am, post-dose | 4.20 ± 4.210 |
| On-Therapy Day 2, 6-8h, am, post-dose | 1.22 ± 0.4729 |
| On-Therapy Day 2, 8-10h, am, post-dose | 1.10 ± 1.103 |
| On-Therapy Day 2, 10-12h, am, post-dose | 1.26 ± 1.358 |
| On-Therapy Day 2, 0-2h, pm post-dose | 2.56 ± 2.717 |
| On-Therapy Day 2, >2h, pm, post-dose | 2.61 ± 2.579 |
| On-Therapy Day 3 to 5, 0-6h post-dose | 4.10 ± 3.955 |
| On-Therapy Day 3 to 5, 6-8h post-dose | 2.54 ± 3.006 |
| On-Therapy Day 3 to 5, 8-10h post-dose | 1.08 ± 0.9247 |
| On-Therapy Day 3 to 5, 10-12h post-dose | 1.17 ± 1.688 |
Urine samples were collected from participants.
| ug/mL | Gepotidacin |
|---|---|
| Baseline Day 1, 0-2hour (h) post-dose | 317 ± 680.3 |
| Baseline Day 1, >2h post-dose | 857 ± 1539 |
| On-Therapy Day 2, am, pre-dose | 391 ± 402.5 |
| On-Therapy Day 2, 0-6h, am, post-dose | 781 ± 1449 |
| On-Therapy Day 2, 6-8h, am, post-dose | 363 ± 443.7 |
| On-Therapy Day 2, 8-10h, am, post-dose | 326 ± 274.4 |
| On-Therapy Day 2, 10-12h, am, post-dose | 287 ± 423.2 |
| On-Therapy Day 2, 0-2h, pm post-dose | 156 ± 216.1 |
| On-Therapy Day 2, >2h, pm, post-dose | 624 |
| On-Therapy Day 3 to 5, 0-6h post-dose | 651 ± 1313 |
| On-Therapy Day 3 to 5, 6-8h post-dose | 259 ± 164.9 |
| On-Therapy Day 3 to 5, 8-10h post-dose | 522 ± 663.1 |
| On-Therapy Day 3 to 5, 10-12h post-dose | 370 ± 498.8 |
An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment.
| Participants | Gepotidacin | Nitrofurantoin |
|---|---|---|
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 266 | 165 |
An SAE is defined as any untoward medical occurrence that, at any dose may result in death or is life-threatening or requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity or is a congenital anomaly/birth defect or any other situation according to medical or scientific judgment or is associated with liver injury and impaired liver function.
| Participants | Gepotidacin | Nitrofurantoin |
|---|---|---|
| Number of Participants With Serious Adverse Events (SAEs) | 2 | 3 |
Blood samples were collected for the analysis of hematology parameters: neutrophil count, lymphocyte count, monocyte count, eosinophil count, basophil count and platelet count. Baseline is defined as the latest pre-dose assessment with a non-missing value.
| Giga cells per Liter (10^9 cells/L) | Gepotidacin | Nitrofurantoin |
|---|---|---|
| Basophils, Baseline | 0.053 ± 0.217 | 0.055 ± 0.0256 |
| Basophils, On-Therapy | -0.001 ± 0.187 | 0.000 ± 0.0204 |
| Basophils, Test of Cure | 0.002 ± 0.0204 | 0.001 ± 0.0244 |
| Eosinophils, Baseline | 0.152 ± 0.1137 | 0.154 ± 0.1338 |
| Eosinophils, On-Therapy | 0.013 ± 0.0680 | 0.017 ± 0.0691 |
| Eosinophils, Test of Cure | 0.024 ± 0.0770 | 0.022 ± 0.0865 |
| Lymphocytes, Baseline | 2.074 ± 0.6603 | 2.133 ± 2.0797 |
| Lymphocytes, On-Therapy | 0.009 ± 0.4233 | -0.026 ± 0.5333 |
| Lymphocytes, Test of Cure | -0.003 ± 0.5106 | 0.067 ± 0.6268 |
| Monocytes, Baseline | 0.528 ± 0.1808 | 0.529 ± 0.1906 |
| Monocytes, On-Therapy | -0.022 ± 0.1445 | -0.018 ± 0.1400 |
| Monocytes, Test of Cure | -0.022 ± 0.1528 | -0.010 ± 0.1678 |
| Neutrophils, Baseline | 4.715 ± 1.9781 | 4.640 ± 1.8018 |
| Neutrophils, On-Therapy | -0.540 ± 1.5771 | -0.519 ± 1.4975 |
| Neutrophils, Test of Cure | -0.703 ± 1.7653 | -0.470 ± 1.7541 |
| Platelets, Baseline | 278.0 ± 70.32 | 279.0 ± 73.76 |
| Platelets, On-Therapy | 2.4 ± 24.46 | 2.6 ± 29.94 |
| Platelets, Test of Cure | 3.0 ± 39.74 | 8.6 ± 47.92 |
Blood samples were collected for the analysis of hemoglobin level. Baseline is defined as the latest pre-dose assessment with a non-missing value.
| Gram per Liter (g/L) | Gepotidacin | Nitrofurantoin |
|---|---|---|
| Hemoglobin, Baseline | 132.2 ± 13.13 | 131.7 ± 14.33 |
| Hemoglobin, On-Therapy | -0.1 ± 5.27 | -0.4 ± 6.39 |
| Hemoglobin, Test of Cure | -0.9 ± 6.63 | -1.6 ± 7.27 |
Blood samples were collected for the analysis of hematocrit level. Baseline is defined as the latest pre-dose assessment with a non-missing value.
| Percentage of hematocrit | Gepotidacin | Nitrofurantoin |
|---|---|---|
| Hematocrit, Baseline | 0.4302 ± 0.04292 | 0.4282 ± 0.4584 |
| Hematocrit, On-Therapy | 0.0003 ± 0.02238 | -0.0007 ± 0.02431 |
| Hematocrit, Test of Cure | -0.0023 ± 0.02689 | -0.0055 ± 0.02757 |
Blood samples were collected for the analysis of erythrocytes count. Baseline is defined as the latest pre-dose assessment with a non-missing value.
| Tera cells per Liter (10^12 cells/L) | Gepotidacin | Nitrofurantoin |
|---|---|---|
| Erythrocytes, Baseline | 4.538 ± 0.4315 | 4.515 ± 0.4324 |
| Erythrocytes, On-Therapy | -0.005 ± 0.1900 | -0.011 ± 0.2247 |
| Erythrocytes, Test of Cure | -0.033 ± 0.2377 | -0.048 ± 0.2528 |
Blood samples were collected for the analysis of MCH. Baseline is defined as the latest pre-dose assessment with a non-missing value.
| Picogram (pg) | Gepotidacin | Nitrofurantoin |
|---|---|---|
| MCH, Baseline | 29.20 ± 2.392 | 29.24 ± 2.499 |
| MCH, On-Therapy | 0.02 ± 0.500 | -0.03 ± 0.536 |
| MCH, Test of Cure | 0.02 ± 0.596 | -0.05 ± 0.644 |
Blood samples were collected for the analysis of MCV. Baseline is defined as the latest pre-dose assessment with a non-missing value.
| Femtoliter (fL) | Gepotidacin | Nitrofurantoin |
|---|---|---|
| MCV, Baseline | 95.02 ± 7.057 | 95.03 ± 7.438 |
| MCV, On-Therapy | 0.17 ± 3.269 | 0.07 ± 3.248 |
| MCV, Test of Cure | 0.17 ± 3.511 | -0.019 ± 3.689 |
Blood samples were collected for the analysis of clinical chemistry parameters. Baseline is defined as the latest pre-dose assessment with a non-missing value
| millimoles per liter (mmol/L) | Gepotidacin | Nitrofurantoin |
|---|---|---|
| Serum Calcium, Baseline | 2.357 ± 0.1118 | 2.374 ± 0.1154 |
| Serum Calcium, On-Therapy | -0.009 ± 0.0914 | -0.012 ± 0.992 |
| Serum Calcium, Test of Cure | -0.016 ± 0.0981 | -0.016 ± 0.1017 |
| Serum Chloride, Baseline | 101.6 ± 3.23 | 101.3 ± 3.08 |
| Serum Chloride, On-Therapy | 0.2 ± 2.59 | 0.0 ± 2.49 |
| Serum Chloride, Test of Cure | 0.4 ± 2.88 | 0.2 ± 2.67 |
| Serum Glucose, Baseline | 5.778 ± 2.3665 | 5.689 ± 1.9348 |
| Serum Glucose, On-Therapy | 0.199 ± 1.4728 | 0.397 ± 1.5986 |
| Serum Glucose, Test of Cure | 0.156 ± 1.5893 | 0.290 ± 1.5996 |
| Serum Magnesium, Baseline | 0.836 ± 0.0760 | 0.831 ± 0.0781 |
| Serum Magnesium, On-Therapy | -0.006 ± 0.0634 | -0.015 ± 0.0604 |
| Serum Magnesium, Test of Cure | -0.008 ± 0.0626 | -0.014 ± 0.0616 |
| Serum Phosphate, Baseline | 1.138 ± 0.1641 | 1.133 ± 0.1750 |
| Serum Phosphate, On-Therapy | 0.005 ± 0.1642 | -0.012 ± 0.1826 |
| Serum Phosphate, Test of Cure | 0.009 ± 0.1857 | 0.008 ± 0.1908 |
| Serum Potassium, Baseline | 4.32 ± 0.441 | 4.33 ± 0.447 |
| Serum Potassium, On-Therapy | 0.00 ± 0.443 | -0.01 ± 0.495 |
| Serum Potassium, Test of Cure | 0.00 ± 0.488 | 0.01 ± 0.495 |
| Serum Sodium, Baseline | 139.5 ± 2.69 | 139.2 ± 2.64 |
| Serum Sodium, On-Therapy | -0.1 ± 2.41 | -0.2 ± 2.54 |
| Serum Sodium, Test of Cure | 0.0 ± 2.68 | -0.1 ± 2.64 |
| Serum Urea Nitrogen, Baseline | 4.855 ± 1.8877 | 4.912 ± 2.1175 |
| Serum Urea Nitrogen, On-Therapy | -0.039 ± 1.1285 | -0.045 ± 1.1848 |
| Serum Urea Nitrogen, Test of Cure | 0.031 ± 1.3613 | 0.054 ± 1.5544 |
Blood samples were collected for the analysis of clinical chemistry parameters. Baseline is defined as the latest pre-dose assessment with a non-missing value.
| micromoles per Liter (umol/L) | Gepotidacin | Nitrofurantoin |
|---|---|---|
| Serum direct bilirubin, Baseline | 4.71 ± 1.534 | 4.78 ± 1.462 |
| Serum direct bilirubin, On-Therapy | -0.26 ± 1.443 | -0.16 ± 1.276 |
| Serum direct bilirubin, Test of cure | -0.24 ± 1.577 | -0.08 ± 1.534 |
| Serum Creatinine, Baseline | 59.5 ± 20.67 | 59.3 ± 20.17 |
| Serum Creatinine, On-Therapy | 2.8 ± 13.51 | 2.3 ± 23.79 |
| Serum Creatinine, Test of Cure | 0.9 ± 16.98 | 2.2 ± 29.46 |
| Serum total bilirubin, Baseline | 6.72 ± 3.914 | 6.77 ± 3.909 |
| Serum total bilirubin, On-Therapy | -0.10 ± 2.718 | -0.15 ± 2.655 |
| Serum total bilirubin, Test of Cure | -0.15 ± 2.904 | -0.16 ± 3.107 |
Blood samples were collected for the analysis of clinical chemistry parameters. Baseline is defined as the latest pre-dose assessment with a non-missing value.
| gram per Liter (g/L) | Gepotidacin | Nitrofurantoin |
|---|---|---|
| Serum Albumin, Baseline | 45.2 ± 3.07 | 45.4 ± 2.91 |
| Serum Albumin, On-Therapy | 0.0 ± 2.21 | -0.3 ± 2.06 |
| Serum Albumin, Test of Cure | -0.5 ± 2.42 | -0.5 ± 2.50 |
| Serum Protein, Baseline | 71.6 ± 4.73 | 71.8 ± 4.72 |
| Serum Protein, On-Therapy | 0.0 ± 3.70 | -0.4 ± 3.46 |
| Serum Protein, Test of Cure | -0.9 ± 4.02 | -1.0 ± 3.76 |
Blood samples were collected for the analysis of clinical chemistry parameters. Baseline is defined as the latest pre-dose assessment with a non-missing value.
| Units per Liter (U/L) | Gepotidacin | Nitrofurantoin |
|---|---|---|
| Serum ALP, Baseline | 79.0 ± 27.98 | 78.4 ± 30.89 |
| Serum ALP, On-Therapy | -0.5 ± 6.91 | 0.1 ± 7.24 |
| Serum ALP, Test of Cure | -1.5 ± 9.43 | 0.0 ± 12.65 |
| Serum AST, Baseline | 20.1 ± 9.40 | 21.5 ± 16.55 |
| Serum AST, On-Therapy | 0.5 ± 5.97 | 0.1 ± 5.33 |
| Serum AST, Test of Cure | 1.1 ± 7.21 | 1.6 ± 38.77 |
| Serum ALT, Baseline | 18.9 ± 13.55 | 20.0 ± 17.84 |
| Serum ALT, On-Therapy | 0.8 ± 5.17 | 0.2 ± 5.43 |
| Serum ALT, Test of Cure | 1.0 ± 8.93 | 1.2 ± 23.91 |
Urine samples were collected for urinalysis: Urine Glucose (GLU), Urine Protein (PRO), Urine Occult Blood (BLO), Urine Ketones (KET), Urine Nitrite (NIT) and Urine Leukocyte Esterase (LEU). Baseline is defined as the latest pre-dose assessment with a non-missing value. The dipstick test gives results in a semi-quantitative manner, and results can be read as Negative, Trace, Small, Moderate, Large, Positive, 50 mg/dL, 150 mg/dL, \>=500 mg/dL, 30 mg/dL, 100 mg/dL, 200 mg/dL, 5 mg/dL, 20 mg/dL and 80 mg/dL indicating concentrations in the urine sample. In the row title (GLU, Baseline, Negative), GLU indicates parameter, Baseline is the visit and Negative indicates the concentration in the urine sample. Data is presented in similar manner for all other parameters.
| Participants | Gepotidacin | Nitrofurantoin |
|---|---|---|
| GLU, Baseline, Negative | 703 | 717 |
| GLU, Baseline, 50 mg/dL | 15 | 5 |
| GLU, Baseline, 150 mg/dL | 4 | 3 |
| GLU, Baseline, >= 500 mg/dL | 21 | 15 |
| GLU, On-Therapy, Negative | 681 | 680 |
| GLU, On-Therapy, 50 mg/dL | 11 | 6 |
| GLU, On-Therapy, 150 mg/dL | 7 | 4 |
| GLU, On-Therapy, >= 500 mg/dL | 22 | 21 |
| GLU, Test of Cure, Negative | 672 | 672 |
| GLU, Test of Cure, 50 mg/dL | 6 | 4 |
| GLU, Test of Cure, 150 mg/dL | 2 | 4 |
| GLU, Test of Cure, >= 500 mg/dL | 21 | 20 |
| PRO, Baseline, Negative | 501 | 501 |
| PRO, Baseline, 30 mg/dL | 179 | 160 |
| PRO, Baseline, 100 mg/dL | 60 | 72 |
| PRO, Baseline, >=500 mg/dL | 3 | 6 |
| PRO, On-Therapy, Negative | 546 | 587 |
| PRO, On-Therapy, 30 mg/dL | 133 | 102 |
| PRO, On-Therapy, 100 mg/dL | 40 | 20 |
| PRO, On-Therapy, >=500 mg/dL | 2 | 2 |
| PRO, Test of Cure, Negative | 602 | 591 |
| PRO, Test of Cure, 30 mg/dL | 77 | 89 |
| PRO, Test of Cure, 100 mg/dL | 21 | 15 |
| PRO, Test of Cure, >=500 mg/dL | 1 | 5 |
| BLO, Baseline, Negative | 310 | 297 |
| BLO, Baseline, Positive | 2 | 0 |
| BLO, Baseline, Small | 248 | 266 |
| BLO, Baseline, Moderate | 118 | 107 |
| BLO, Baseline, Large | 72 | 75 |
| BLO, On-Therapy, Negative | 531 | 475 |
| BLO, On-Therapy, Small | 123 | 167 |
| BLO, On-Therapy, Moderate | 38 | 40 |
| BLO, On-Therapy, Large | 29 | 29 |
| BLO, Test of Cure, Negative | 503 | 510 |
| BLO, Test of Cure, Small | 124 | 114 |
| BLO, Test of Cure, Moderate | 46 | 50 |
| BLO, Test of Cure, Large | 28 | 26 |
| KET, Baseline, Negative | 724 | 726 |
| KET, Baseline, 5 mg/dL | 14 | 8 |
| KET, Baseline, 20 mg/dL | 4 | 5 |
| KET, Baseline, >=80 mg/dL | 1 | 1 |
| KET, On-Therapy, Negative | 704 | 688 |
| KET, On-Therapy, 5 mg/dL | 10 | 20 |
| KET, On-Therapy, 20 mg/dL | 6 | 2 |
| KET, On-Therapy, >=80 mg/dL | 1 | 1 |
| KET, Test of Cure, Negative | 683 | 688 |
| KET, Test of Cure, 5 mg/dL | 13 | 11 |
| KET, Test of Cure, >=80 mg/dL | 5 | 1 |
| NIT, Baseline, Negative | 466 | 458 |
| NIT, Baseline, Positive | 286 | 291 |
| NIT, On-Therapy, Negative | 655 | 647 |
| NIT, On-Therapy, Positive | 66 | 64 |
| NIT, Test of Cure, Negative | 662 | 639 |
| NIT, Test of Cure, Positive | 39 | 61 |
| LEU, Baseline, Negative | 186 | 169 |
| LEU, Baseline, Trace | 80 | 77 |
| LEU, Baseline, Small | 89 | 74 |
| LEU, Baseline, Moderate | 109 | 116 |
| LEU, Baseline, Large | 292 | 314 |
| LEU, Baseline, Positive | 0 | 2 |
| LEU, On-Therapy, Negative | 429 | 387 |
| LEU, On-Therapy, Trace | 82 | 86 |
| LEU, On-Therapy, Small | 48 | 69 |
| LEU, On-Therapy, Moderate | 57 | 63 |
| LEU, On-Therapy, Large | 105 | 106 |
| LEU, Test of Cure, Negative | 506 | 442 |
| LEU, Test of Cure, Trace | 60 | 73 |
| LEU, Test of Cure, Small | 38 | 54 |
| LEU, Test of Cure, Moderate | 38 | 50 |
| LEU, Test of Cure, Large | 59 | 81 |
Urine samples were collected from participants to assess urine specific gravity. Baseline is defined as the latest pre-dose assessment with a non-missing value.
| Ratio | Gepotidacin | Nitrofurantoin |
|---|---|---|
| Urine Specific Gravity, Baseline | 1.0168 ± 0.00639 | 1.0166 ± 0.00636 |
| Urine Specific Gravity, On-Therapy | 1.0175 ± 0.00663 | 1.0166 ± 0.00636 |
| Urine Specific Gravity, Test of Cure | 1.0179 ± 0.00700 | 1.0179 ± 0.00701 |
Urine samples were collected from participants to assess urine pH levels. Baseline is defined as the latest pre-dose assessment with a non-missing value.
| pH | Gepotidacin | Nitrofurantoin |
|---|---|---|
| Urine pH, Baseline | 5.6 ± 0.76 | 5.7 ± 0.79 |
| Urine pH, On-Therapy | 5.6 ± 0.68 | 5.6 ± 0.73 |
| Urine pH, Test of Cure | 5.6 ± 0.68 | 5.6 ± 0.70 |
SBP and DBP were measured in a semi-supine position after 5 minutes rest. Baseline is defined as the latest pre-dose assessment with a non-missing value.
| Millimeters of mercury (mmHg) | Gepotidacin | Nitrofurantoin |
|---|---|---|
| SBP, Baseline | 123.1 ± 13.23 | 123.4 ± 12.61 |
| SBP, On-Therapy | -0.8 ± 9.20 | -1.4 ± 9.64 |
| SBP, Test of Cure | -0.9 ± 10.44 | -1.2 ± 10.86 |
| DBP, Baseline | 76.5 ± 8.36 | 76.7 ± 8.25 |
| DBP, On-Therapy | -0.2 ± 7.48 | -0.7 ± 7.33 |
| DBP, Test of Cure | -0.5 ± 7.80 | -1.2 ± 8.28 |
Pulse rate was measured in a semi-supine position after 5 minutes rest. Baseline is defined as the latest pre-dose assessment with a non-missing value.
| beats per minute (bpm) | Gepotidacin | Nitrofurantoin |
|---|---|---|
| Pulse rate, Baseline | 73.5 ± 9.84 | 73.3 ± 9.91 |
| Pulse rate, On-Therapy | 1.4 ± 8.39 | 1.7 ± 8.80 |
| Pulse rate, Test of Cure | 1.2 ± 9.63 | 1.0 ± 10.18 |
Temperature was measured in a semi-supine position after 5 minutes rest. Baseline is defined as the latest pre-dose assessment with a non-missing value.
| celsius | Gepotidacin | Nitrofurantoin |
|---|---|---|
| Temperature, Baseline | 36.62 ± 0.372 | 36.62 ± 0.406 |
| Temperature, On-Therapy | -0.04 ± 0.300 | -0.04 ± 0.379 |
| Temperature, Test of Cure | -0.04 ± 0.330 | -0.07 ± 0.400 |
Collected over All cause mortality, non-serious adverse events (Non-SAEs) and serious adverse events (SAEs) were collected from the time of first dose (Day 1) through the final follow-up visit (Day 21-31).. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Gepotidacin | 0/766 (0%) | 2/766 (0.3%) | 207/766 (27%) |
| Nitrofurantoin | 0/760 (0%) | 3/760 (0.4%) | 94/760 (12.4%) |
| Event | Gepotidacin | Nitrofurantoin |
|---|---|---|
| LymphadenopathyBlood and lymphatic system disorders | 0/766 | 1/760 |
| Dengue feverInfections and infestations | 0/766 | 1/760 |
| Food intoleranceMetabolism and nutrition disorders | 0/766 | 1/760 |
| Lumbar radiculopathyNervous system disorders | 0/766 | 1/760 |
| SciaticaNervous system disorders | 0/766 | 1/760 |
| Enterovesical fistulaGastrointestinal disorders | 1/766 | 0/760 |
| DysarthriaNervous system disorders | 1/766 | 0/760 |
| Event | Gepotidacin | Nitrofurantoin |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 111/766 | 27/760 |
| NauseaGastrointestinal disorders | 81/766 | 29/760 |
| Abdominal pain upperGastrointestinal disorders | 20/766 | 8/760 |
| HeadacheNervous system disorders | 17/766 | 18/760 |
| FlatulenceGastrointestinal disorders | 15/766 | 4/760 |
| Faeces softGastrointestinal disorders | 14/766 | 4/760 |
| DizzinessNervous system disorders | 11/766 | 8/760 |
| VomitingGastrointestinal disorders | 10/766 | 3/760 |
| Urinary tract infectionInfections and infestations | 8/766 | 5/760 |
| Aspartate aminotransferase increasedInvestigations | 8/766 | 5/760 |
Participants randomly assigned to the study treatment were included in the ITT population.
| Age, Customized(Years) | Gepotidacin | Nitrofurantoin | Total |
|---|---|---|---|
| Mean | 49.6 ± 17.82 | 50.4 ± 18.17 | 50.0 ± 17.99 |
| Age, Customized(Participants) | Gepotidacin | Nitrofurantoin | Total |
|---|---|---|---|
| Less than (<) 18 years | 6 | 9 | 15 |
| More than or equal to (>=) 18 years to 50 years | 372 | 369 | 741 |
| More than (>) 50 years | 389 | 386 | 775 |
| Sex/Gender, Customized(Participants) | Gepotidacin | Nitrofurantoin | Total |
|---|---|---|---|
| Female | 767 | 764 | 1531 |
| Ethnicity (NIH/OMB)(Participants) | Gepotidacin | Nitrofurantoin | Total |
|---|---|---|---|
| Hispanic or Latino | 278 | 270 | 548 |
| Not Hispanic or Latino | 489 | 494 | 983 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Gepotidacin | Nitrofurantoin | Total |
|---|---|---|---|
| American Indian or Alaska Native | 62 | 75 | 137 |
| Asian | 23 | 21 | 44 |
| Native Hawaiian or Other Pacific Islander | 3 | 1 | 4 |
| Black or African American | 40 | 40 | 80 |
| White | 627 | 621 | 1248 |
| More than one race | 12 | 6 | 18 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Baseline Acute Cystitis Recurrence(Participants) | Gepotidacin | Nitrofurantoin | Total |
|---|---|---|---|
| Recurrent Infection | 312 | 309 | 621 |
| Non-Recurrent Infection | 455 | 455 | 910 |
Showing the first 100 of 104 sites across 12 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · clinicalstudydatarequest.com
Ran from Oct 2019 to primary completion in Nov 2022, 37 months.
Results were first posted in Jun 2023, 6 months after primary completion.
Of 23 industry-sponsored phase 3 interventional studies under Urinary Tract Infections, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's 37 months is above that.
Counting every sponsor, half of 37 studies reached it within 20 months; a quarter within 14 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gepotidacin